Hormone Replacement Therapy - Pipeline Analysis and Market Forecasts to 2016
The Hormone Therapy Drugs Market is Forecast to Show Marginal Growth Until 2016 GlobalData estimated the global hormone therapy (HT) market to be worth $2.1 billion in 2009, indicating a Compound Annual Growth Rate (CAGR) of -6.8% between 2001 and 2009. This decline in the market is mainly attributed to poor patient compliance as a result of the serious safety concerns associated with hormones. By 2016, the market is forecast to record $2.3 billion, with a CAGR of 1.2% between 2009 and 2016. The market is restrained by factors such as the poor acceptance of hormone therapies in patients as well as physicians. Also, the approaching patent expiries of several hormone therapies and increased interest in non-HT therapies are expected to favor the marginal growth of HT market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Hormone-Replacement-Therapy--Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare The Current Competition in the Hormone Therapy Market is Strong GlobalData found that the current competition in the hormone therapy market is strong. Several products are available in different dosage forms such as oral tablets, vaginal creams, rings and tablets, transdermal patches, sprays, syringes, intrauterine systems and combination products. Hormone therapy has been the treatment of choice since the 1960s. Premarin and Prempro have been the market leaders in postmenopausal women. The major players in the hormone therapy market include Pfizer (Wyeth) and Novo Nordisk. Hormone therapy has been the most efficacious therapy for treating postmenopausal symptoms to date. There have been safety concerns associated with the use of HT, but the low dose and ultra-low dose versions of hormones used for a short time have gone some way in meeting the unmet need. However, there has been no good data to prove the safety of these minimized doses of HT.
Few Promising Hormonal Products in Late Stage Development: Stability of the HT Market at Stake? GlobalData analyzed that the HT pipeline is weak with few promising hormonal products under development, let alone first in class hormonal products. Low-dose hormone drugs such as Angeliq lowlow and combination hormonal drugs are being developed but a major share of the pipeline is of nonhormonal molecules. This trend shift towards non-hormonal therapeutics for menopausal symptoms and osteoporosis has been quite apparent after the Women’s Health Initiative Study (WHI) (2002). The HT market has been rapidly declining and reseacher’s quest for the treatment of postmenopausal symptoms is still continuing. Low-dose hormone drugs were successful in stabilizing the market to a certain extent but not all women desire or are candidates of HT. Should a hormonal drug with better safety and efficacy be approved, the HT market will gain momentum and might see a boost in revenues. Aprela is the only promising Phase III molecule and its launch is believed to restore the HT market. Otherwise, non-hormonal treatments contribute to majority of the pipeline and if approved by the US FDA, are predicted to hamper the postmenopausal hormone therapy market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Hormone-Replacement-Therapy--Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Huge Unmet Need in Terms of Safety: Shift in Focus of R&D Towards Nonhormonal Therapies Hormone therapy is the only US FDA-approved treatment and was considered to be one of the most efficacious pharmacological interventions for treating menopausal symptoms and osteoporosis. The currently marketed hormone therapeutics are very effective at treating menopausal symptoms, be it vasomotor symptoms, hot flashes or osteoporosis. However, they are associated with serious side effects such as increased breast cancer risk and coronary heart disease. The safety of the currently approved products is low and thus accounts for the reduced patient compliance. The WHI study in 2002
significantly hampered the HT market and led to increased concerns among HT patients. Although the WHI reanalysis in 2007 suggested that HT users under the age of 60 years will not have heart safety issues, postmenopausal women are still worried about using HT. GlobalData, the industry analysis specialist’s new report, “Hormone replacement therapy – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global hormone replacement therapy market. The report identifies the key trends shaping and driving the global hormone replacement therapy market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global hormone replacement therapy sector. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Hormone-Replacement-Therapy--Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam firstname.lastname@example.org +914066166782